EFG Asset Management North America Corp. Purchases 48,295 Shares of Vericel Co. (NASDAQ:VCEL)

EFG Asset Management North America Corp. grew its position in Vericel Co. (NASDAQ:VCEL) by 83.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 106,064 shares of the biotechnology company’s stock after purchasing an additional 48,295 shares during the quarter. EFG Asset Management North America Corp. owned approximately 0.21% of Vericel worth $5,819,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of VCEL. Arcadia Investment Management Corp MI bought a new stake in Vericel during the fourth quarter valued at $48,000. Smartleaf Asset Management LLC boosted its position in shares of Vericel by 511.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company’s stock valued at $70,000 after purchasing an additional 1,058 shares in the last quarter. Geneos Wealth Management Inc. grew its stake in Vericel by 826.6% during the fourth quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 2,240 shares during the period. Quantbot Technologies LP acquired a new stake in Vericel during the third quarter worth approximately $146,000. Finally, KBC Group NV lifted its stake in Vericel by 82.5% in the fourth quarter. KBC Group NV now owns 2,707 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 1,224 shares during the period.

Insider Buying and Selling at Vericel

In other news, Director Robert L. Md Zerbe sold 2,500 shares of the company’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total transaction of $156,250.00. Following the transaction, the director now owns 26,595 shares of the company’s stock, valued at $1,662,187.50. This represents a 8.59 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jonathan Siegal sold 1,092 shares of Vericel stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $61.99, for a total value of $67,693.08. Following the completion of the sale, the insider now directly owns 1,206 shares of the company’s stock, valued at approximately $74,759.94. This trade represents a 47.52 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 34,092 shares of company stock worth $1,683,582 over the last three months. 5.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have recently commented on VCEL. Truist Financial reaffirmed a “buy” rating and set a $61.00 price objective (down previously from $67.00) on shares of Vericel in a research report on Monday, March 3rd. StockNews.com raised shares of Vericel from a “sell” rating to a “hold” rating in a research note on Saturday, March 8th. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of Vericel in a report on Friday, February 28th. Stephens reiterated an “overweight” rating and issued a $65.00 target price on shares of Vericel in a report on Wednesday, January 15th. Finally, Canaccord Genuity Group raised their price target on shares of Vericel from $64.00 to $67.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Vericel has a consensus rating of “Moderate Buy” and an average target price of $62.29.

Vericel Stock Performance

VCEL opened at $47.94 on Tuesday. Vericel Co. has a fifty-two week low of $39.12 and a fifty-two week high of $63.00. The firm has a 50-day moving average of $54.16 and a 200 day moving average of $51.73. The firm has a market cap of $2.40 billion, a P/E ratio of 799.13 and a beta of 1.78.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.